Meiogenix

What Meiogenix does

Meiogenix is a privately held agricultural biotechnology company founded in 2010 and headquartered in Paris, with operational presence in the United States through Research Triangle Park, North Carolina. The company has developed a proprietary targeted meiotic recombination platform built around a dCas9-SPO11-1 fusion protein that directs chromosome crossovers to specific genomic sites, enabling breeders to access roughly one-quarter of beneficial genes that are normally locked in suppressed recombination "cold" regions of crop genomes. The technology is non-GMO because it stimulates a natural process rather than introducing foreign DNA, which materially reduces regulatory cost and time-to-market relative to gene editing or transgenic approaches. Proof of concept has been demonstrated across three strategic crops: rice (approximately 3.2-fold recombination increase on chromosome 7), corn (10-fold recombination efficiency improvement announced February 2026), and tomato (via the BTI/FFAR collaboration).

The company monetizes through a B2B technology licensing model, generating revenue from license fees, development milestones, and royalties paid by commercial seed companies and breeding teams. Go-to-market combines direct enterprise engagement, co-development partnerships integrating the platform into partner R&D pipelines, and academic collaborations with institutions such as Cornell University, University of Hamburg, CIRAD, Institut Curie, and Boyce Thompson Institute. Named enterprise customers include Bayer, with whom Meiogenix signed a 2020 collaboration. Meiogenix has raised $13 million in Series A financing (December 2021) led by Sofinnova Partners, with 30+ patents protecting the platform globally. The senior leadership team, drawn substantially from Corteva Agriscience, Syngenta, and other major agribusinesses, is in the process of commercializing the platform against a stated $50 billion addressable commercial seed market.

Name

Meiogenix

Legal name

Meiogenix

Website

https://meiogenix.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Meiogenix is a Paris-based agricultural biotechnology company that licenses a proprietary dCas9-SPO11-1 targeted meiotic recombination platform to global seed companies, enabling non-GMO access to previously inaccessible crop genetic diversity and accelerating breeding cycles from over a decade to three to seven years.

Ownership category

akta.pro rank

Product category

Agricultural Biotechnology

akta.pro primary industry

Biotechnology & Gene-Edited Trait Development (AFAGAIAG)

akta.pro secondary industry

Transformation & Tissue Culture Platforms (Plant regeneration, delivery systems) (AFABALAH)

Keywords

• Targeted recombination platform
• Plant breeding technology
• Crop genetic improvement
• Meiotic recombination
• Agricultural biotechnology

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Technology Licensing: Large-scale technology licensing partnerships delivering value through license fees, milestones, and royalties. The company provides breeding technology to seed companies worldwide through its proprietary recombination platform, empowering breeders with technology access.
2. Co-development Partnerships: Collaborative development agreements with commercial breeding teams and seed companies to co-develop elite lines for specific markets and environments, integrating recombination technology into existing R&D pipelines.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Meiogenix provides a proprietary targeted recombination platform for plant breeding based on dCas9-SPO11-1 fusion technology that locally stimulates meiotic recombination at user-defined genomic loci. The company licenses this platform to commercial seed companies and partners with breeding teams through co-development agreements, charging license fees, milestones, and royalties. Core capabilities include trait introgression, linkage drag elimination, complex trait assembly, and access to cold genome regions that were previously inaccessible to conventional breeders.

Product overview

Meiogenix offers a unified targeted recombination platform for plant breeding, comprising the core dCas9-SPO11-1 technology system and supporting service modules. The platform is complemented by crop innovation services, technology licensing programs, and specialized trait development offerings including trait introgression, linkage drag resolution, complex trait assembly, and cold zone recombination access. The company operates through value-driven partnerships with seed companies, academic institutions, and NGOs, providing technology licensing with fees, milestones, and royalties.

Differentiator

Problem solved

Functional benefit

Products and services

• Targeted Recombination Platform

Quantifiable outcome

• 10x increase in targeted recombination efficiency in corn
• +3 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Eight partnerships are on record, tiered core.

• Strategic Advisory Board (Monsanto, Corteva, CoverCress, Aramis Biotech, CNRS)coreOthers · 9 December 2025Industry veterans from Monsanto, Corteva, CoverCress, Aramis Biotech, Cornell University, and France's CNRS assembled to guide advancement of Meiogenix's targeted recombination platform. The advisory board brings over a century of combined expertise across genetics, plant breeding, and commercialization.
• Boyce Thompson Institute (BTI)coreStrategic or Co-development Partner · 13 August 2025$2 million collaboration with BTI to develop drought- and disease-resistant tomatoes by tapping genetic power of wild species. Project combines high-throughput screening of wild tomato species with Meiogenix's targeted recombination platform to transfer valuable traits to elite germplasm.
• Foundation for Food & Agriculture Research (FFAR)coreStrategic or Co-development Partner · 13 August 2025FFAR Seeding Solutions grant funder for the $2 million tomato genetics collaboration with BTI. FFAR builds public-private partnerships to fund bold research addressing food and agriculture challenges, matching federal funding with private investment.
• CIRADcoreStrategic or Co-development Partner · 31 May 2025Research collaboration contributing to the peer-reviewed publication on dCas9-SPO11-1 targeted recombination in rice. CIRAD researchers were part of the multidisciplinary team that conducted the groundbreaking study published in Frontiers in Plant Science.
• Cornell UniversitycoreStrategic or Co-development Partner · 20 February 2020Multiyear research partnership with Cornell professor Wojtek Pawlowski to develop technologies for targeted genetic recombination in maize chromosomes. Meiogenix invested over $1 million in the collaboration. Pawlowski's lab at Cornell has been studying genetic recombination mechanisms for 15 years.
• University of HamburgcoreStrategic or Co-development Partner · 20 February 2020Academic research partnership to engineer maize with desirable traits including disease resistance and climate resilience. The partnership combines Meiogenix's targeted recombination expertise with University of Hamburg's research capabilities.
• Institut CuriecoreStrategic or Co-development Partner · 20 February 2020French research institution collaboration providing scientific foundation for Meiogenix's targeted recombination technology. Co-founder Dr. Alain Nicolas is a CNRS Research Director and group leader at Institut Curie, who identified the first initiation site of meiotic recombination in yeast.
• BayercoreStrategic or Co-development Partner · 10 February 2020Bayer and Meiogenix collaboration to advance agricultural R&D by accelerating development of Meiogenix's proprietary breeding and genome editing technologies. The collaboration enables Bayer breeders to improve precision and speed of crop enhancement, with potential to deliver improved plant health and nutrition to food crops.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Pairwise: Pairwise is a gene-editing crop company using CRISPR-based tools to develop improved plant varieties, directly competing in the trait-development and licensing space served by Meiogenix. Both target seed companies with precision breeding technologies.
• Inari Agriculture: Inari combines AI-driven predictive design with multiplex gene editing to deliver step-change yield improvements in major row crops. It is a direct competitor to Meiogenix in crop trait innovation and seed-company licensing.
• Tropic Biosciences: Tropic Biosciences applies gene editing to tropical crops (banana, coffee, rice) and is a direct peer in trait-development licensing for specialty and field crops, comparable in stage and GTM to Meiogenix.
• Benson Hill: Benson Hill uses AI/ML-enabled crop design and ingredient innovation platforms to deliver proprietary seed varieties. It is comparable to Meiogenix as a plant-breeding innovation company commercializing through seed licensing.
• Cibus: Cibus uses its Rapid Trait Development System (gene editing) to develop non-transgenic crop traits, directly overlapping with Meiogenix's non-GMO trait development and licensing business model.
• KeyGene: KeyGene is a Dutch plant-genomics company that develops molecular breeding and targeted recombination technologies for crop improvement. It is a direct peer in advanced breeding tool development and licensing.

Broad incumbents

• Bayer Crop Science: Bayer Crop Science is the world's largest seed and crop protection business and a current Meiogenix partner. It is a broad incumbent that operates internal breeding R&D and could acquire or compete with Meiogenix.
• Corteva Agriscience: Corteva is a global seed and crop protection major with deep internal breeding capabilities and former CTO Neal Gutterson now chairs Meiogenix. Broad incumbent with overlapping plant genetics capabilities.

Emerging players

• Evogene: Evogene uses AI-driven computational biology for crop protection, plant yield, and human therapeutics. Comparable as a computational biology platform serving seed-company customers, though with broader scope than Meiogenix.
• GreenLight Biosciences: GreenLight Biosciences is an RNA-based agricultural biotech with a plant-health platform. Comparable as an agricultural-biotech licensing business targeting sustainability and crop performance, though using a different core modality than Meiogenix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/meiogenix

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meiogenix